- Get in Touch with Us
Last Updated: Apr 25, 2025 | Study Period: 2024-2030
Nanomedicine is the application of nanotechnology for medical reasons, and it is described as the use of nanoparticles for illness diagnosis, monitoring, control, prevention, and therapy.
Nanomedicine offers the potential to improve early detection and prevention, as well as diagnosis, therapy, and follow-up for a wide range of disorders, including cancer. In total, hundreds of nanomedicine items are currently undergoing clinical trials, spanning all main disorders such as cardiovascular, neurological, musculoskeletal, and inflammatory.
The North America Nanomedicine Market accounted for $XX Billion in 2021 and is anticipated to reach $XX Billion by 2026, registering a CAGR of XX% from 2024 to 2030.
Pfizer Inc. and Acuitas Therapeutics, a company focused on developing lipid nanoparticle (LNP) delivery systems to enable messenger RNA (mRNA)-based therapeutics, have announced a Development and Option agreement under which Pfizer will have the option to licence Acuitas' LNP technology for up to 10 vaccine or therapeutic targets on a non-exclusive basis.
Sirtex Medical, a leading manufacturer of targeted liver cancer therapies in the United States announced a lead and strategic investment in Nanospectra Biosciences, Inc., a medical device company pioneering a novel use of nanomedicine for selective thermal ablation.
Nanospectra's lead product AuroLase for prostate cancer tissue ablation, which is the first and only ultra-focal ablation therapy designed to maximise treatment efficacy while minimising side effects commonly associated with surgery, radiation, and alternative focal therapies, will benefit from the investment.
The National Cancer Institute (NCI) and GE Global Research, the company's technology development arm, have announced a two-year cooperative research and development agreement to accelerate the development of cutting-edge nanoparticle based imaging agents that have the potential to revolutionise the diagnosis and treatment of cancer and heart disease.
| Sl no | Topic |
| 1 | Market Segmentation |
| 2 | Scope of the report |
| 3 | Abbreviations |
| 4 | Research Methodology |
| 5 | Executive Summary |
| 6 | Introduction |
| 7 | Insights from Industry stakeholders |
| 8 | Cost breakdown of Product by sub-components and average profit margin |
| 9 | Disruptive innovation in theIndustry |
| 10 | Technology trends in the Industry |
| 11 | Consumer trends in the industry |
| 12 | Recent Production Milestones |
| 13 | Component Manufacturing in US, EU and China |
| 14 | COVID-19 impact on overall market |
| 15 | COVID-19 impact on Production of components |
| 16 | COVID-19 impact on Point of sale |
| 17 | Market Segmentation, Dynamics and Forecast by Geography, 2024-2030 |
| 18 | Market Segmentation, Dynamics and Forecast by Product Type, 2024-2030 |
| 19 | Market Segmentation, Dynamics and Forecast by Application, 2024-2030 |
| 20 | Market Segmentation, Dynamics and Forecast by End use, 2024-2030 |
| 21 | Product installation rate by OEM, 2022 |
| 22 | Incline/Decline in Average B-2-B selling price in past 5 years |
| 23 | Competition from substitute products |
| 24 | Gross margin and average profitability of suppliers |
| 25 | New product development in past 12 months |
| 26 | M&A in past 12 months |
| 27 | Growth strategy of leading players |
| 28 | Market share of vendors, 2022 |
| 29 | Company Profiles |
| 30 | Unmet needs and opportunity for new suppliers |
| 31 | Conclusion |
| 32 | Appendix |
© 2017-2025 Mobility Foresights Pvt Ltd. All rights reserved.